Administration Of Fecal Microbiota By Colonoscopy Safe, Effective For Treating Patients With Recurrent Clostridioides Difficile Infection, Study Finds

Healio (5/5, Shinkle) reports that administration of Rebyota (fecal microbiota, live-jslm) “by colonoscopy appears safe and effective among adults with recurrent Clostridioides difficile infection, according to results from the CDI-SCOPE trial presented at Digestive Disease Week.” Researchers said that “95% of study participants achieved treatment success at 8 weeks after administration.” Following treatment, “90% of patients noticed symptom improvement within the first month, and 52% reported improvement in the first week.” Furthermore, 90% of physicians “who performed the colonoscopy procedures reported a ‘positive’ or ‘very positive’ experience with administration, including preparation time and ease of passage through the colonoscope.”